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HEPATIC ENCEPHALOPATHY: NOVEL INSIGHTS INTO 
CLASSIFICATION, PATHOPHYSIOLOGY AND THERAPY. 
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ABSTRACT 
Hepatic encephalopathy (HE) is a frequent and serious complication of both chronic liver disease and 
acute liver failure. HE manifests as a wide spectrum of neuropsychiatric abnormalities, from 
subclinical changes (mild cognitive impairment) to marked disorientation, confusion and coma. The 
clinical and economic burden of HE is considerable, and it contributes greatly to impaired quality of 
life, morbidity and mortality. This review will critically discuss the latest classification of HE, as well 
as the pathogenesis and pathophysiological pathways underlying the neurological decline in patients 
with end-stage liver disease. In addition, management strategies, diagnostic approaches, currently 
available therapeutic options and novel treatment strategies are discussed. 
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ABBREVIATIONS 
ACLF, acute-on-chronic liver failure; ALF, acute liver failure; ATP, adenosine triphosphate; BBB, blood-brain barrier; 
BCAA, branched-chain amino acids; BOLD, blood oxygenation level dependent; CLDs, chronic liver diseases; CRP, C-
reactive protein; CSF, cerebrospinal fluid; ECAD, extracorporeal liver assist device; FMT, faecal microbiota 
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transplantation; GS, glutamine synthetase; HE, hepatic encephalopathy; GABA, gamma-aminobutyric acid; GAMSA, 
ABAA receptor-modulating steroid antagonists; GCS, Glasgow Coma Score; Gln, glutamine; LOLA, L-ornithine L-
aspartate; LSPD, liposome-supported peritoneal dialysis; LT, liver transplantation; mHE, minimal hepatic encephalopathy; 
MELD, model for end-stage liver disease; MR, magnetic resonance; NAFLD, non-alcoholic fatty liver disease; NMDA, N-
methyl-D-aspartate; OP, ornithine phenylacetate; PEG, polyethylene glycol; TIPS, transjugular intrahepatic portosystemic 
shunt; TSH, thyroid-stimulating hormone; TSPO, translocator protein. 
KEY POINTS 
Hepatic encephalopathy is an important complication and cause of death in patients with cirrhosis. 
Even the minimal form of hepatic encephalopathy, which is not clinically detectable, is associated with 
driving difficulties, poor quality of life and independently associated with mortality. 
Ammonia is central in the pathogenesis of hepatic encephalopathy; its levels define prognosis and it is 
an important therapeutic target. 
Inflammation-derived from liver injury, hyperammonaemia or infection is a frequent precipitating 
factor. 
Hepatic encephalopathy is not always reversible and multiple episodes are associated with poor 
neurological outcomes even after liver transplantation. 
Mainstay treatment for episodes of hepatic encephalopathy is lactulose and rifaximin with many new 
approaches under development and in clinical trials. 
INTRODUCTION 
Hepatic encephalopathy (HE) is broadly defined as brain dysfunction caused by liver insufficiency 
and/or portal-systemic shunting, which manifests as a wide spectrum of neurological or psychiatric 
abnormalities ranging from subclinical alterations to coma.
1
 This definition of HE does not consider the 
underlying cause of the liver disease. However, the aetiological factors leading to chronic liver diseases 
(CLDs), such as alcohol-related liver disease, non-alcoholic fatty liver disease, viral hepatitis and 
primary biliary cholangitis can all affect the brain through mechanisms independent from those 
triggered by liver failure/dysfunction
.2, 3, 4, 5
 Defined as a metabolic disorder, HE is widely considered 
to be reversible following liver transplantation (LT). However, this notion is changing as numerous 
studies have demonstrated that neuroinflammation and neuronal cell death are features of 
HE and episodes of overt HE can lead to irreversibility. These manifest as persisting neurological 
complications post-LT.
6,7
 This fundamentally changes our understanding of HE as a reversible 
syndrome. 
From the epidemiological perspective, it has become clear that HE is probably the most frequent 
complication of cirrhosis that leads to hospitalisations and repeated re-admissions.
8
 Therefore, the 
healthcare burden and costs associated with the management of HE are extensive and increasing.
9
 More 
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importantly, it has been demonstrated that HE is associated with high rates of mortality, irrespective of 
the severity of liver disease, indicating that HE is not merely a symptom of liver failure, but that it may 
have independent pathophysiological and prognostic implications.
10
 
From the pathophysiologic perspective, data from recent studies indicate that ammonia remains the 
central player in the pathogenesis of HE. However, systemic and neuroinflammation, as well as 
oxidative stress and cellular senescence, are known to be implicated. In addition, blood-brain barrier 
(BBB) permeability/function, cerebrospinal fluid composition, glymphatic flow, cerebral energy 
metabolism, neurotransmission and cell-cell communication are all deranged, causing neurological 
impairment and providing potential therapeutic targets
.11, 12, 13, 14, 15, 16, 17
 
The AASLD-EASL clinical guidelines for HE, published in 2014, were an important initiative.
1
 
However, since this publication, there have been many advances in the classification of HE, as well as 
our understanding of its pathophysiology, diagnosis and treatment. For instance, „covert‟ HE, a term 
which was first introduced in 2014, has been studied further. In addition, acute-on-chronic liver failure 
(ACLF) has recently been defined and needs to be considered. Furthermore, based on a better 
understanding of the pathophysiology of HE and a clearer view of inter-organ ammonia metabolism, 
many new therapeutic agents are being developed. 
The purpose of this review is to provide a detailed and critical insight into the current state-of-the-art 
and discuss each of the issues described above, as well as point out avenues for future research. This 
review will focus on discussing HE in association with CLD (Type C HE). Where relevant, reference to 
HE in association with acute liver failure (ALF) (referred to as Type A HE) and HE that occurs in 




EPIDEMIOLOGY AND COST ASSOCIATED WITH HEPATIC ENCEPHALOPATHY 
HE results in utilisation of more healthcare resources compared to other complications of liver disease.
9
 
The incidence of HE is 11.6 per 100 person years which increases to 40% by 5 years.
18
 The prevalence 
of overt HE at the time of diagnosis of cirrhosis is 10–14%,
19,20
 16–21% in decompensated cirrhosis
21
 
and 10–50% in patients who have had a transjugular intrahepatic portosystemic shunt (TIPS) 
inserted.
22,23
 Estimates of the prevalence of minimal hepatic encephalopathy (mHE) in patients with 
cirrhosis range from 20% to 80%.
24, 25, 26
 This variability reflects the definition of what constitutes 
mHE as discussed later in the review. The risk of developing the first episode of overt HE is about 25% 
within 5 years after the diagnosis of cirrhosis, depending on the presence of risk factors such as mHE, 
grade 1 HE, diabetes, hyponatremia, and hepatitis C.
27, 28, 29
 Patients with a previous episode of overt 
HE have a 42% risk of recurrence at 1 year, and those with recurrent overt HE have a 46% risk of 
another episode within 6 months, despite receiving standard care.
30,31
 Even patients with cirrhosis and 
mild cognitive dysfunction or slight electroencephalogram slowing have a 1-year risk of developing an 
episode of overt HE of about 33%.
30,32
 
As HE is a manifestation of serious liver impairment, its outcome depends on the severity of 
underlying liver disease, its clinical course, and its treatment. Population-based cohorts of patients with 
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cirrhosis presenting with overt HE have a median survival time of just a few months and a 2-fold 
increased risk of mortality over 1-year compared to cirrhotic patients without HE.
10,20
 
The healthcare resource requirements of patients with HE are relevant from a public health perspective. 
In the USA, from 2010–2014, there was a 30% increase in HE-related hospitalisations.
8
 Such numbers 
are not available for the European Union but are expected to be similar. Furthermore, the burden of 
CLD and cirrhosis is increasing in most countries, primarily due to a rise in non-alcoholic 
steatohepatitis-related cirrhosis
33
; therefore, more cases with HE will likely emerge in the future. 
Patients hospitalized with HE in the US generated charges of about US $11.9 billion per year, a 46% 
increase from 2010–2014
8
 Recent data confirm this estimate, but also provide evidence that 
readmission rates with HE at 90 days are about 27% and cost an additional USD $200M.
34
 Such costs 
will increase because of changes in the cirrhosis case-mix towards more advanced liver disease and 
correspondingly more complex healthcare efforts. There are no direct EU cost data, but the 
epidemiology suggests comparable costs, supported by inference from regional patient sampling,
35
 also 
showing that the yearly cost of patients with HE is 50% higher than of patients with heart failure or 
chronic obstructive pulmonary disease.
36
 These figures are a gross underestimate of total HE costs, 
because costs associated with primary healthcare, disability and lost productivity as well as the 
negative impact on the patient's family or support network are not included.
37
 
CLASSIFICATION OF HEPATIC ENCEPHALOPATHY 
HE occurs in the setting of ALF, portal-systemic shunting without liver disease and most commonly in 
cirrhosis.
1
 However, the categorisation of disease severity across the spectrum of HE in cirrhosis is 
challenging. HE has traditionally been graded into overt (clinically manifest neurological-psychiatric 
abnormalities) and mHE (abnormalities on neuropsychological or electrophysiological tests without 
clinically detectable neurological-psychiatric abnormalities).
38
 As the clinical diagnosis of mild forms 
of overt HE is heavily operator-dependent, it has been suggested
1
 that HE is qualified as overt when at 
least temporal disorientation and/or asterixis are detected (≥grade II according to the West Haven 
criteria). However, the grades of HE, defined according to these criteria are not reproducible across 
observers and are thought to be inappropriate for clinical trials.
1,39
 Hence, newer classifications have 
been developed, which are more accurate in the assessment of overt HE. (i) The hepatic 
encephalopathy scoring algorithm (HESA),
40
 (ii) the clinical hepatic encephalopathy staging scale 
(CHESS),
41
 (iii) the hepatic encephalopathy staging tool (HEST) and (iv) the hepatic encephalopathy 
grading instrument (HEGI)
42
 have been developed, validated and are being used in ongoing clinical 
trials. 
The estimation of the condition in its milder stages is also fraught with inter-observer issues.
39
 At the 
heart of this is the semi-quantitative nature of the West Haven criteria, which have not defined grade I 
HE well. The term „covert HE‟ was suggested because of its sound (opposite to overt).
43
 Therefore, in 
patients with deranged psychometric or neuropsychological tests but with no grade 2 HE, the umbrella 
term of „covert HE‟ was introduced.
43
 Covert HE requires testing for its detection and quantification, 
and the diagnosis cannot be made clinically
1
 and its validity has been determined using standardized 
patient testing modalities (Table 1).
39,42
 However, it has been shown that covert HE is a heterogeneous 
entity,
44
 and that grade I HE abnormalities have additional prognostic
44,45
 and possibly also therapeutic 
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implications compared to abnormalities on testing for mHE alone. In addition, since patients with grade 
I alterations are symptomatic, albeit mildly, there is no reason not to treat them like any patient with a 
symptomatic medical condition. Thus, in clinical practice, particularly where neuropsychological 
and/or neurophysiological tests are not performed systematically,
46
 grade I abnormalities should not be 
neglected if accurately diagnosed and should contribute to both treatment- and prognosis-related 
decisions. Importantly, regulatory agencies such as the FDA, have moved away from grade I HE and 
require at least grade 2 or higher to define HE events for multicentre clinical trials.
42
 Even more 




Table 1. Neuropsychological tests used for the diagnosis of minimal hepatic encephalopathy. 





paper & pencil 
The PHES consists of 5 paper-pencil tests evaluating 
cognitive/psychomotor processing speed and visuomotor 
coordination. They are relatively easy to administer, have good 
external validity and have been translated/validated into several 
languages and countries.251 




The ANT (i.e. the number of animals listed in 60 seconds, no 
equipment required except a stopwatch) has recently been shown to 
compare favourably with more established mHE measures and to 
predict overt HE.186 




The CRT test relies on repeated registration of the motor reaction 
time (pressing a button) to auditory stimuli (through headphones). 
The most important test result is the CRT index, which measures the 
stability of the reaction times. Age and sex seem to exert limited 
influence and there are no learning/tiring effects either.245 




ICT is a computerised test of response inhibition and working 
memory and is freely downloaded at www.hecme.tv. The ICT test 
has been judged to have good validity but requires highly functional 
patients.246 
Stroop test Neuropsychological, 
computerised 
The Stroop test evaluates psychomotor speed and cognitive 
flexibility by the interference between recognition reaction time to a 
coloured field and a written colour name; also available in app 
form.26 
SCAN test Neuropsychological, 
computerised 
The SCAN test is a computerised test that measures speed and 
accuracy to perform a digit recognition memory task of increasing 
complexity. It has been shown to have prognostic value.247 
Electroencephalogram 
(EEG) 
Neurophysiological The EEG can detect changes in cortical cerebral activity across the 
spectrum of HE and its reliability increases with quantitative 
analysis. More recently, a cheap gaming device has been shown to 
produce similar results compared to a standard EEG machine across 
the HE spectrum.248 
Critical flicker frequency 
(CFF) 
Psychophysical CFF is defined as the frequency at which a flickering light (from 60 
Hz downwards) appears to be flickering to the observer. Studies 
have shown its reduction with worsening cognition and 
improvement after therapy. It requires specialized equipment.249 
mHE, minimal hepatic encephalopathy. 
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The operative criteria proposed for the diagnosis of grade 1 HE by the AASLD/EASL clinical practice 
guideline
1
 (“despite being oriented in time and space, the patient appears to have some 
cognitive/behavioural decay with respect to his/her standard on clinical examination or to the 
caregivers”) aims to overcome some of the difficulties that were inherent in the original description, 
which comprised a list of vague signs and symptoms.
48
 If one follows the proposed definition, the 
problem of diagnosing grade 1 HE becomes particularly problematic in patients who do not have a 
caregiver. In these patients, careful observation and clinical examination are the only tools available to 
diagnose grade 1 HE and how these patients are classified will be based on Consensus statements. This 
current dilemma in the definitions and the lack of specific tests to diagnose and grade covert/low grade 
HE makes this a very challenging condition for which to define endpoints and develop new therapies; 
its pathophysiologic basis is therefore also undefined. Furthermore, how liver disease aetiology is 
implicated in these subtle neurologic abnormalities remains unclear. 
HEPATIC ENCEPHALOPATHY ASSOCIATED WITH ACUTE-ON-CHRONIC LIVER FAILURE 
Patients with „overt HE‟ are not homogeneous and the clinical, prognostic and pathophysiological 
characteristics of HE that are observed in patients with and without ACLF are likely to be 
different.
10,49,50
 ACLF is a newly defined syndrome that occurs in hospitalised patients with cirrhosis 
and is characterised by organ failures, systemic inflammation and high mortality rates.
51, 52, 53
 Increased 
intracranial pressure implies cerebral oedema and is a characteristic feature of ALF. In CLD, numerous 
studies have demonstrated HE is associated with an increase in brain water
54, 55, 56, 57 
without 
intracranial hypertension. However, a retrospective study comparing patients with CLD and ACLF 
with high grade HE (3/4) showed that cerebral oedema was evident in less than 5% patients, although 
this study relied on CT scans which are an insensitive measure of brain swelling.
58
 In a prospective 
study, Sawhney et al. observed that higher ammonia levels, more marked systemic inflammation and 
reduced jugulo-venous oxygen saturation distinguished ACLF patients with HE from those without.
49
 
The most convincing argument that ACLF is associated with distinct changes in the brain comes from 
studies in animal models. Data from the ACLF models clearly demonstrate evidence of astrocytic 
swelling and vasoconstriction of cerebral microvessels on electron microscopy with increased 
expression of inducible nitric oxide synthase. Moreover, these pathophysiological changes are 
therapeutically relevant as strategies to reduce ammonia or inflammation abrogate these changes and 
are potential therapeutic targets.
59, 60, 61
 The most convincing clinical argument suggesting that patients 
with HE and ACLF are clinically and prognostically different to those without ACLF are provided by 
Cordoba et al. where they analysed the data from the CANONIC study and demonstrated that the 
presence of ACLF in patients with HE increased both short- and long-term mortality.
10
 More recently, 
these data have been confirmed by a large study from the NACSELD group and a further smaller 
prospective study from the UK.
49,62
 Taken together, the data argue that these syndromes are clinically 
and pathophysiologically distinct. However, more studies are needed to better understand the 
pathophysiological basis and clinical characteristics of HE in patients with ACLF. 
DISEASE-RELATED MENTAL DYSFUNCTION AND ROLE OF COMORBIDITIES 
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It is clear that liver failure is associated with HE, but the causes underlying the development of liver 
disease such as alcohol abuse, obesity and viral hepatitis (particularly hepatitis C), as well as 
extrahepatic conditions such as diabetes and ageing, may impact on the manifestations of HE (Fig.1). 
At present, it is not clear whether the neurologic dysfunction observed in the different aetiologies of 
cirrhosis or in association with diabetes or ageing are different. 
 
Fig. 1. Brain dysfunction increases with cumulative pathogenic factors. 
Severity of liver disease, comorbidities (diabetes, kidney failure), age, degree of hyperammonaemia, severity of 
inflammation/oxidative stress and severity/type of precipitating event can independently affect and sensitise the brain. 
Simultaneous pathogenetic factors can synergistically cause a greater impact on brain function and an increased risk of 
hepatic encephalopathy. 
ALCOHOL ABUSE 
As alcohol is a common cause of cirrhosis and a direct neurotoxin, difficulties in diagnosis may arise in 
distinguishing what element is directly related to alcohol and what component results from liver injury. 
This problem is particularly evident in the context of LT, where incomplete recovery of 
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neuropsychometric function and MRI abnormalities were observed in patients with alcohol-related 
liver disease.
6,7
 Post-mortem studies from brain banks have revealed greater evidence of structural 
brain injury in those dying from alcohol-related cirrhosis, compared with other aetiologies.
63
 These 
changes may impact on the assessment of these patients when using neuropsychometric tests to 
diagnose mHE and grade 1 HE. In the acute situation, where patients appear clinically confused, 
withdrawal from alcohol and the Wernicke-Korsakoff syndrome may make the diagnosis of HE 
difficult.
64
 However, loss of orientation in space and time is rarely a feature of alcohol withdrawal 
syndrome but is a characteristic of overt HE. 
NON-ALCOHOLIC FATTY LIVER DISEASE 
Non-alcoholic fatty liver disease (NAFLD) is fast becoming the most common cause of cirrhosis. More 
recently, studies have demonstrated that psychometric function in obese children is impaired
65,66
 and 
data also indicate lower brain volume in patients with NAFLD.
67, 68, 69
 Recently published studies have 
started to indicate that even in the non-cirrhotic stages of NAFLD, urea cycle enzyme function is 
impaired, which results in hyperammonaemia that is reversible with resolution of NAFLD.
70
 In such 
patients, astrocytic and microglial activation have been observed.
2
 Taken together, it is probable that 
NAFLD has serious negative functional impact on the brain that results from hyperammonaemia and 
neuroinflammation. Even in patients without cirrhosis, changes in the brain are observed in association 
with NAFLD.
67,71,72
 These data need to be confirmed in carefully characterised groups of patients to 
dissect the associated mechanisms and define whether there are specific features related to NAFLD and 
how these impact on the diagnosis of early stages of HE in this patient population. 
HEPATITIS C 
Many studies over the past 2 decades have confirmed a clear association between hepatitis C virus 
infection and neuropsychiatric symptoms.
3
 The reported symptoms vary widely, manifesting as fatigue, 
depression and loss of attention. It has become clear that these symptoms are independent of severity of 
liver disease and characterised by abnormalities on brain imaging and neuroinflammation that are 
distinct from patients with cirrhosis. Indeed, they resemble the changes observed in patients with HIV. 
Further proof for the role of hepatitis C in producing neuropsychiatric disturbances comes from the 
demonstration of the virus in the post-mortem brains and the observation that the virus can replicate in 
many cell types including the endothelial cells, astroglia and microglia.
73
 This possibly explains the 
neuroinflammation observed in these patients. It is important to note that eradication of the virus results 
in substantial improvement in neuropsychiatric function. 
OBESITY, DIABETES AND AGE 
Ageing, obesity and diabetes are emerging as important contributors to the development of HE. 
Diabetes is frequently associated with cirrhosis and clinical studies suggest that the risk of developing 
HE is significantly greater in these patients.
28,74
 Likewise, the risk of HE is greater with ageing and the 
insertion of TIPS in older patients is a relative contraindication because of the risk of HE 
development.
75
 Concomitant medications can modulate the cognitive function and course of HE as 
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well.
76, 77, 78, 79
 The mechanisms underlying the increased risk of HE in these populations is not clear, 
but likely result from worsening cerebrovascular disease, systemic inflammation, the effect of 
senescence and oxidative stress.
80
 Further elucidation of the relevant pathogenic pathways would 
enable the development of new therapeutic strategies to prevent HE in these patients. 
PATHOPHYSIOLOGY (FIG. 2) 
SYSTEMIC PATHOGENIC FACTORS 
Neurological impairment and cognitive decline provoked by liver dysfunction are the result of blood-
derived factors influencing the permeability and/or altering the integrity of the BBB. In cirrhosis, 
factors which are normally prevented from crossing the BBB enter the brain and other molecules (such 
as ammonia), which naturally cross the BBB, flood the brain and stimulate pathophysiological 
pathways, causing deleterious effects. 
 
Fig. 2. Pathogenesis and pathophysiology of hepatic encephalopathy. 
 BBB, blood-brain barrier; CSF, cerebrospinal fluid; HE, hepatic encephalopathy; NMDA, N-methyl-D-aspartate; TIPS, 
transjugular intrahepatic portosystemic shunt. 
Chronic liver disease leads to hepatocyte dysfunction, portal hypertension, portal-systemic shunting, 
altered microbiota, bacterial translocation, malnutrition, sarcopenia, electrolyte imbalance as well as 
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constipation and gastrointestinal bleeding. Consequently, pathogenic factors are generated including 
hyperammonemia, systemic inflammation/oxidative stress as well as increased blood manganese, 
circulating bile acids and lactate. These systemic factors influence the blood-brain barrier (BBB) by 
increasing its permeability (increased signaling across the BBB, physical breakdown of the BBB which 
allows for an increased influx of molecules which normally do and do not cross the BBB). Independent 
of BBB status, ammonia passes freely into the brain which is exclusively removed by astrocytes via 
glutamine synthetase. The generation of glutamine renders the astrocyte hypertonic resulting in 
swelling and impaired function and brain oedema. Astrocyte swelling leads to compromised neuronal 
communication leading to neuronal dysfunction. Alterations of cerebrospinal fluid (CSF) metabolites 
are observed, as well as alterations in neurotransmission such as increased GABergic tone potentiated 
with neurosteroids and glutamate-induced N-methyl-D-aspartate (NMDA) stimulation. Blood derived 
increase in brain ammonia is central in the pathophysiological mechanisms underlying the development 
of HE. Neuroinflammation and microglia activation are significant modulators in the onset of 
neurological decline. Astrocyte senescence as well as neuronal cell death may be key features in the 
irreversibility of HE. However, the extent and underlying causes of neuronal cell death remain to be 
defined. 
Ammonia 
Although the pathophysiology of HE remains incompletely understood, neurotoxic levels of ammonia 
in the brain are a feature.
81
 Ammonia is primarily produced in the gut, as an end product of protein 
digestion, amino acid deamination and bacterial urease activity. Subsequently, a healthy liver, with an 
intact urea cycle, regulates the concentration of ammonia in the systemic circulation, thus maintaining 
blood ammonia levels in the low 35–50 μM range. However, ammonia is also generated and utilised in 
a number of biochemical reactions, (i.e amidation of glutamate and deamidation of glutamine via 
glutamine synthetase [GS] and glutaminase, respectively), which are active in multiple organs 
(including the brain, muscle and kidney). In the setting of liver disease, inter-organ ammonia 
metabolism is altered.
82
 In aqueous solutions, ammonia is present as a dissolved gas (NH3) and an ion 
(NH4
+
), with the former freely diffusing across plasma membranes. NH4
+
 is transported into cells 
through aquaporins, ammonia transporters, K
+
 channels and co-transporters. Ammonia exerts its 
deleterious effects through multiple pathways including cellular swelling, inflammation, oxidative 
stress, mitochondrial dysfunction, disruption of cellular bioenergetics, changes in pH and alterations in 
membrane potential.
83
 A direct correlation between the degree of hyperammonaemia and the severity 
(grade) of HE has not been confirmed but it is clear the diagnosis of HE is incompatible with normal 
ammonia levels. This lack of correlation may reflect the idea that different patients have different 
sensitivities to the same levels of ammonia. The deleterious effects of high ammonia extend to organs 
such as the liver, immune system and muscles.
84,85
 
Inflammation and oxidative stress 
The inflamed liver, together with gut bacterial translocation and superimposed infection,
86
 aggravates 
systemic inflammation, which in turn produces BBB dysfunction and drives neuroinflammation. 
Oxidative stress, a systemic phenomenon that is frequently observed in cirrhosis, can compromise BBB 
permeability as reactive oxygen (and nitrogen) species are highly reactive with lipids, proteins and 
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DNA.
87
 Signs of cerebral oxidative stress have been documented in patients with overt HE
88
 but a 
disconnect between systemic and cerebral oxidative stress has been revealed.
89
 Underlying 
hyperammonaemia has been shown to induce neutrophil dysfunction and release reactive oxygen 
species, triggering systemic oxidative stress and inflammation which exacerbate the deleterious effects 
of hyperammonaemia on the brain.
90, 91, 92, 93
 
Bile acids 
Bile acids are a metabolic product of cholesterol metabolism and are synthesised in the liver via 
cytochrome p450 activity in hepatocytes. Bile acids are elevated in the blood of patients with end-stage 
liver disease due to disrupted enterohepatic circulation. Bile acids have been detected in the brains of 
rats with HE induced by bile-duct ligation,
94




Metals play an important role as co-factors for numerous enzymatic reactions. Manganese is a co-factor 
for the ammonia-removing enzymatic reaction of GS. Manganese is normally excreted via a biliary 
route, but this is impaired in end-stage liver disease, leading to manganese deposition within the basal 
ganglia, which is believed to explain the psychomotor impairment associated with HE.
96,97
 However, 
the reason for the accumulation of manganese in specific brain regions and the mechanisms underlying 
manganese neurotoxicity in the context of cirrhosis remain unresolved. Zinc is a cofactor for the 
antioxidant enzyme superoxide dismutase. Zinc deficiency has been observed in patients with HE
253
 





Patients with cirrhosis often present with dilutional hyponatremia, which interferes with the other 
suspected pathogenic mechanisms of HE, particularly those centred around the osmotic effects of 
ammonia. There is linear risk relation between low plasma sodium concentrations over a wide range 
and the risk for HE.
98
 Resolution of hyponatremia in patients with cirrhosis without HE leads to 
improved complex information processing.
99
 Treatment with vasopressin receptor antagonists does not 
reduce the frequency of HE but tolvaptan led to improvements in cognition and health-related quality 
of life in a small study.
100,101
 Improved management of and research on hyponatremia in patients with 
HE remains relevant. 
NEUROPATHOPHYSIOLOGY 
It is important to note that the blood and brain compartments are separate entities, ammonia aside, what 
occurs in the blood does not necessarily occur in the brain. It has been shown that cerebrospinal fluid 
composition is significantly different in cirrhotic patients with HE compared to those without. In 
addition, in patients with overt HE, cerebrospinal fluid metabolomics highlighted alterations of 
metabolites that were not observed in plasma samples.
15
 Recent evidence describes a defective 
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glymphatic system (which facilitates clearance of various substances that accumulate in the brain) that 
may contribute to the development of HE.
12
 Significant increases in concentrations of neurosteroids 
have been reported in autopsied brain tissue from cirrhotic patients with HE, which increase 
GABAergic tone by positively modulating the GABAA receptor complex.
102
 
Cerebral energy and lactate metabolism 
In HE, an increase in brain water is observed primarily due to swelling of the astrocytes with the 
underlying causes pointing primarily to the hypertonic accumulation of intracellular glutamine and/or 
lactate as a result of hyperammonaemia.
103,104
 A swollen astrocyte can independently impact 
on astrocyte function disconnecting astrocyte-neuronal cell communication, altering cell metabolism 
and neurotransmission.
105
 Elevated levels of lactate in the brain during HE may depict energy 
impairment, which is thought to be a result of reduced oxidative metabolism in neurons, as astrocytes 
appear unaffected.
106
 Recently, analysis of plasma samples showed that alterations in the concentration 
of metabolites linked to energy metabolism were specifically and significantly increased in 
cerebrospinal fluid samples of patients with HE.
15
 Furthermore, this may denote disturbances in lactate 




Neuronal cell death 
Neuronal cell death has been largely disregarded in HE, but with increasing cases and evidence of 
“untreatable HE”, along with neurological complications arising post-LT, permanent brain injury needs 
to be included in the pathogenesis of HE.
7,108, 109, 110, 111, 112
 There is increasing evidence that recurrent 
episodes of overt HE prior to LT are associated with persistent neurocognitive abnormalities post-
LT.
113, 114, 115
 Neurodegeneration is probably the operative mechanism, as seen in a rodent model of 
episodic HE.
116
 Moreover, ammonia neurotoxicity has been shown to induce astrocyte senescence,
14
 
which leads to neuronal cell death. The mechanisms of neuronal cell death remain unresolved and will 
be an important line of research in the years to come. 
THE GUT-LIVER AXIS AND THE ROLE OF THE MICROBIOME 
The gut milieu has a major impact on brain function in patients with HE.
117
 This is borne out by 
extensive clinical experience with drugs that modify the gut, which can in turn improve brain function.
1
 
The constituents of the gut microbiome include bacteria, fungi and viruses, particularly 
bacteriophages.
118,119
 These interact with each other, the host as well as with the food and medications 
to which the host is exposed. With the advent of culture-independent techniques, improved 
understanding of the gut microbiome has
119
 led to new thinking in terms of disease pathogenesis, 
progression and the mechanism of action of some commonly used medications for HE. Importantly, 
both the structure (which taxa are present) and the function (what are they producing/consuming) are 
relevant in the study of the microbiome in HE.
117
 Specific bacterial families belonging to phylum 
Proteobacteria (Enterobacteriaceae, which includes E. coli, K. pneumoniae etc.) are potentially harmful 
since they produce very damaging endotoxins. On the other hand, certain families belonging to gram-
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positive Clostridia (Lachnospiraceae, Ruminococcaceae) are thought to be autochthonous and 




In cirrhosis, the aetiology of the disease modulates the capacity of diseased and inflamed liver to 
produce bile acids, while the ability to clear bacterial antigens arriving from the gut is impaired. This 
leads to an increase in potentially pathogenic Proteobacteria. Toxins such as ammonia and 
inflammatory cytokines produced by this impaired intestinal milieu access the circulation and 
exacerbate or precipitate HE.
121
 
Bacterial taxa in cirrhosis show impaired composition (higher potentially pathogenic and lower 
autochthonous taxa) in the stool, large and small intestinal mucosa, ascites and the liver itself.
122, 123, 124, 
125
 However, similar microbial changes are also found in locations distant from the gut-liver axis such 
as the saliva and the serum, likely due to an underlying immuno-suppressed state.
126, 127, 128
 Microbial 
functionality is also impaired with changes in bile acid profile and endotoxin production, which mirror 
cirrhosis severity.
129
 Bacterial profiles can predict hospitalisations, death and organ failure in cirrhosis 
and may be of clinical relevance.
124,130,131
 Recent evidence shows that fungal dysbiosis may also play a 
role in cirrhosis progression.
132
 Thus, the composition and functionality of microbiota in HE may 
modulate the clinical disease course, brain function and effect therapeutic interventions. 
MALNUTRITION 
Malnutrition is a common occurrence in CLD. The underlying reasons for the onset of malnutrition 
include inadequate dietary intake, increased energy expenditure, impaired digestion and 
malabsorption.
133
 Consequently, an increased metabolic rate leads to the catabolism of muscle proteins, 
which is compounded by depletion of glycogen stores and impairment in glycogenolysis. In addition, 
elevated ammonia levels can impact on the muscle, causing deleterious effects (including impairing 
muscle protein synthesis) setting up a detrimental vicious cycle.
85
 In patients with cirrhosis, nutritional 
supplements are indicated to achieve a target of 35–45 kcal/kg and 1.2–1.5 g/kg protein per day, as well 
as late night snacks.
134




Sarcopenia (muscle mass depletion) is nearly universal in patients with cirrhosis. Characterised by a 
deterioration in muscle quantity and quality, sarcopenia is also associated with decreased functional 
capacity
136,137
 and has been shown to be an independent prognostic factor for survival in patients with 
cirrhosis.
138
 Moreover, muscle mass loss has a significant impact on the risk of developing HE.
139
 
Muscle, due to the fact it houses GS (an important ammonia removing enzyme), plays a vital 
compensatory role in ammonia detoxification during liver disease. Indeed, cirrhotic patients with 
sarcopenia have higher ammonia levels and increased risk of developing HE.
140, 141, 142, 143
 In addition, 
muscle catabolism during muscle wasting promotes increased glutamine release which can generate 
ammonia via glutaminase, contributing to hyperammonaemia. Results from recent pre-clinical studies 
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suggest that ammonia-lowering treatments should be tested to prevent and treat sarcopenia, which 
would reduce the risk of HE.
144
 
Sarcopenia can also manifest as frailty, which is an independent predictor of mortality in patients with 
cirrhosis.
145,146
 The relationship between frailty and sarcopenia is stronger in men than in women.
145
 
The direct impact of frailty on the risk of HE is unknown. 
IMPACT OF HEPATIC ENCEPHALOPATHY ON NEUROLOGICAL OUTCOME FOLLOWING LIVER 
TRANSPLANTATION 
HE, defined as a metabolic disorder, is presumed to completely resolve following LT. However, 
persisting neurological complications remain problematic following LT, affecting as many as 47% (8–
47%) of LT recipients.
147,148
 Consequently, these enduring neurological complications following LT 
(not defined as HE since the diseased liver has been replaced with a healthy liver) not only severely 
weigh on the patients' health-related quality of life but also lead to longer hospitalisations. Numerous 
studies have documented patients with cirrhosis and a history of HE display impaired neurological 
recovery, suggesting that repeated episodes of HE lead to permanent cell damage.
7,108, 109, 110, 111, 112
 
Therefore, irreversible brain damage may not be resolved with LT, leading to continued neurological 
disturbances. It is thought that patients with cirrhosis and no history of HE pre-LT rarely develop 
neurological complications following LT. However, post-LT immunosuppression induced 
neurotoxicity, particularly from calcineurin inhibitors, should not be disregarded as a causal factor.
149
 
In addition, perioperative conditions, including seemingly innocuous hypotensive insults, may be 
detrimental for a compromised brain. Whether neurological complications observed in LT recipients 
are residual symptoms from a history of HE (pre-LT) or newly developed perioperatively (HE-
influenced) or related to a comorbidity is difficult to define accurately. Having said this, a recent study 
reported a recovery of brain function in patients followed-up long-term (>5 years) post-LT.
150
 
INSIGHTS FROM NEUROIMAGING STUDIES 
The diverse neurological manifestations of CLD present a diagnostic challenge for modern 
hepatologists, with magnetic resonance techniques representing a highly profitable avenue to 
investigate structural and functional aspects of brain dysfunction in an objective way (Table 2).
151,152
 
While there is widespread acceptance of its importance, there is little consensus on how best to 
diagnose and monitor HE. Of note, modern clinical MRI scanners with multinuclear MR spectroscopy 
capabilities and brain mapping software can objectively demonstrate structural and functional cellular 
changes (such as brain size and astrocyte swelling) using volumetric MRI, magnetization transfer MRI, 





spectroscopy, with the option of performing many sequences at a single sitting to maximise 
information gathering and cohort characterisation.
153, 154, 155, 156, 157, 158
 PET studies have provided clear 
evidence of increased ammonia uptake in the brain and alterations in regional cerebral blood flow, as 
well as evidence of neuroinflammation, microglial activation and altered benzodiazepine receptors, 
confirming the role of these putative mechanisms in the pathogenesis of HE.
152,156
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Table 2. Information provided by different imaging techniques. 









Measures shifts in bound and free water content, which have been associated with intracellular and 
extracellular oedema and with alterations in cell membrane fluidity. In patients with HE there is 
evidence of reduced magnetisation transfer, indicating increased brain water.154 
Diffusion-weighted 
MR imaging 
Measures ADCs of water molecules. Associated with structural damage to white matter tracts. 
Changes in ADCs have been observed in patients with HE.252 
Functional MR 
imaging (fMRI) 
Measures changes in blood flow in metabolically active areas of the brain, related to oxygenation and 
de-oxygenation of haemoglobin (BOLD response). Resting state or responses to cognitive tasks can 




Measures high energy metabolites, such as ATP and phosphocreatine, together with cell membrane 
precursors (phosphomonoesters) and cell membrane degradation products (phosphodiesters). 
Widespread changes in 31P metabolites have been shown to occur in patients with HE.158 
1H MR 
spectroscopy 
Measures lactate, choline, glutamine and glutamate levels and fluxes in osmolytes such as myo-
inositol and taurine. Neuronal integrity reflected by N-acetyl aspartate measurements. Cannot 
measure ammonia levels directly, but increased glutamine represents amidation by glutamine 
synthetase. This is the best validated imaging test that may be useful for the diagnosis of HE as the 
severity of HE has been shown to correlate with changes in metabolites.157 
Positron emission 
tomography (PET) 
Depending on the radioligand used, information can be obtained on a wide variety of brain activity 
including neurotransmitter binding (such as dopamine or GABA receptors), TSPO activity (as a 
measure of neuroinflammation) and glucose utilisation. Several studies using PET have revealed 
alterations in cerebral blood flow, perfusion, glucose utilisation, oxygenation, ammonia metabolism, 
benzodiazepine receptor expression and neuroinflammation in patients with HE.250 
ADCs, apparent diffusion coefficients; ATP, adenosine triphosphate; BOLD, Blood oxygenation level dependent; GABA, 
gamma-aminobutyric acid; HE, hepatic encephalopathy; MR, magnetic resonance; TSPO, translocator protein. 
Investigations using MRI have shown evidence of hyperintensity of the basal ganglia, possibly related 
to the deposition of manganese, which correlated with the severity of extrapyramidal symptoms.
154
 
Other studies showed altered magnetization transfer ratio suggesting regional brain swelling, which in 
the early stages was also evident in the white matter.
153
 In patients with ACLF, MRI studies have 
shown clear evidence of brain oedema.
151
 In general, the MRI studies have suggested that there is a loss 
of brain volume, which continues even after LT, particularly in those with alcohol-related cirrhosis.
155
 
Proton MR spectroscopy has clearly shown evidence of osmolyte shifts in patients with cirrhosis, 
which manifest as increased glutamine and reduced myoinositol, the severity of which seem to 
correlate with the severity of HE.
157
 Disturbances in choline metabolism and possible neuronal loss 
have also been suggested.
151
 Phosphorus MR spectroscopy has confirmed disturbances of lipid 
metabolism in the brain and also corroborated other studies suggesting disturbances of cerebral 
bioenergetics.
158
 Recent studies using quantitative CT scanning with Brainview have provided evidence 
of altered blood-cerebrospinal fluid barrier permeability in patients with acute decompensation of 
cirrhosis even in the absence of overt HE, suggesting a generalised defect in brain homeostasis in 
patients with advanced cirrhosis.
159
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However, these imaging techniques have so far yielded disappointing performance in diagnostic 
paradigms and therefore remain largely the preserve of research studies.
73,159, 160, 161, 162
 Nevertheless, 
there is the possibility that imaging may be useful for monitoring in trials.
163,164
 More importantly, the 
suggestion that the abnormalities detected using imaging techniques are evident even in patients 
without manifest HE suggests that imaging may well be useful to identify patients at risk of HE so that 
appropriate prophylactic measures can be put in place. In support of this hypothesis, a study using 
proton MR spectroscopy suggested that the glutamine/myoinositol ratio in the brain may help define 
patients at risk of developing ammonia-induced neuropsychometric abnormalities.
160
 In clinical 
practice, at present, brain imaging is largely used to exclude other causes of brain dysfunction rather 
than to diagnose HE. 
MANAGEMENT OF HEPATIC ENCEPHALOPATHY 
DIAGNOSIS OF OVERT HEPATIC ENCEPHALOPATHY 
As mentioned, the diagnosis of HE is challenging, particularly in the covert/minimal forms. Diagnosis 
of overt HE is relatively straightforward and usually a diagnosis of exclusion. In complex situations, 
particularly when there are no obvious precipitating events leading to HE, the diagnosis may be more 
difficult. In alcoholics, it may be difficult to distinguish HE from withdrawal. Cross-sectional imaging 
of the brain should be performed in patients in whom the diagnosis is not clear and is absolutely 
necessary in patients that present with localising signs. A 2-step approach to the differential diagnosis 
has been suggested
64
 (Fig. 3). Response to treatment may be a powerful tool for diagnosis and 
differential diagnosis. A disease that responds to ammonia-lowering treatment is likely to be HE; thus, 
when the syndrome is mild and diagnostic tools limited, treatment may help confirm the diagnosis. 
However, the time needed to decipher whether a patient responds to a treatment or not is critical time, 
as episodes lasting longer than 48 hours lead to higher mortality.
165
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Fig. 3. Two step approach for the diagnosis and evaluation of a patient presenting with a possible 
hepatic encephalopathy. 
CRP, C-reactive protein; MELD, model for end-stage liver disease; TSH, thyroid-stimulating hormone. 
(Modified from Romero-Gomez et al. J Hepatol 2015).244 
ROLE OF AMMONIA MEASUREMENT 
The EASL-AASLD guidelines
1
 are not clear on the role of ammonia measurement in HE. In patients 
suspected of overt HE, a normal ammonia concentration can be used to rule out the diagnosis of HE 
because the negative predictive value of a normal ammonia concentration is high (0.81).
166
 The best 
evidence for the prognostic role of ammonia and its relationship with severity of HE is observed in 
patients with ALF. It is clear that ammonia level of >120 μmol/L seems to identify a group of patients 
at a high risk of developing intracranial hypertension and cerebral oedema
.167, 168, 169
 In patients with 
cirrhosis, recent data have demonstrated the important prognostic role of elevated blood ammonia. 
Although the level of ammonia does not follow the severity of HE, more severe HE is associated with 
higher ammonia levels.
49,166,170, 171, 172, 173, 174
 It is interesting to note that advanced degrees of HE are 
associated with relatively low ammonia levels in cirrhosis compared with ALF, suggesting other 
factors in addition to ammonia may be pathophysiologically important in cirrhosis-induced HE.
49,173,174
 
In any case, elevated ammonia levels have been shown to be associated with reduced transplant-free 
survival in acutely decompensated cirrhosis.
173, 174, 175 
Importantly, a response to intervention that is 
associated with a reduction in ammonia concentrations is associated with good outcomes,
41,176
 while 
the reverse is true if ammonia increases further.
49,177
 This observation is supported by studies of various 
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interventions such as lactulose, rifaximin or extracorporeal albumin dialysis where reduction in 
ammonia was indeed associated with improvement in the severity of HE.
31,178,179
 In a prospective study, 
an ammonia cut-off of 80 μmol/L was shown to be associated with a high risk of death, irrespective of 
the severity of HE.
174
 This suggests that ammonia is more than just a neurotoxin and can serve as a 
biomarker of outcome in patients with cirrhosis and acute decompensation. Therefore, increasing 
evidence that ammonia can exert its toxic effects on extracerebral organs and tissues strongly support 
its management, not only to reduce the risk of HE, but also to prevent multiple organ injury and 
mortality.
84
 It is important to note that ammonia measurement is not easy and requires careful sample 
handling and rapid measurement using a reliable analyser to obtain accurate results.
180,181
 This is 
especially important in multicentre studies that rely on ammonia levels to guide entry into trials or to 
determine success because of the variations within and between individuals and clinical centres.
180,182
 
TREATMENT OF AN EPISODE OF OVERT HEPATIC ENCEPHALOPATHY 
General measures 
The main aims of treatment are managing bouts of overt HE efficiently; reducing its duration, limiting 
its consequences, preventing recurrence and hospital readmissions, limiting effects on patients' quality 
of life, social and professional functioning and, limiting its impact on patients' families and caregivers. 
Treatment of an episode of overt HE in a patient with CLD includes: 
(i) Initiation of care for altered consciousness, which includes securing the airway, 
haemodynamic stabilisation, and ensuring patient safety to prevent physical injury. Patients 
with HE III or higher or Glasgow Coma Score (GCS) ≤8 should be intubated in order to 
prevent aspiration, but this is not possible in many hospitals. In these environments, careful 
attention to airway protection and close monitoring should be instituted. 
(ii) Evaluation of alternative causes of altered mental status, including a CT scan of the head for 
first time presentation of HE and if there is a history of seizures, headache, fall, or 
neurological evaluation reveals a focal deficit. 
(iii) Identification and correction of precipitating events, such as, infection, gastrointestinal 
bleed, constipation, dehydration, sedatives, alcohol intoxication or electrolyte disturbances. 
(iv) (iv)Treatment of HE. 
Once a patient recovers from an episode of HE, the risk of relapse is high; therefore, approaches to 
prevent the recurrence of HE and the associated hospitalisations are of paramount importance. 
At present, no strategies have been specifically tested but approaches for home monitoring of 
biochemical, inflammatory and neurological strategies are becoming available. As ammonia is a major 
neurotoxin, further development of strategies to measure capillary ammonia would be desirable. Indeed 
such tests now exist.
183
 Changes in heart rate variability reflect inflammation and have been shown to 
be associated with HE.
184
 This type of device can be worn and the patient can be monitored remotely; 
one such device was shown to be useful in patients with cirrhosis.
185
 Finally, neurological monitoring 
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at home can be undertaken using the animal naming test
186
 or a wearable electroencephalogram.
187
 
These approaches warrant evaluation in clinical trials. 
Specific treatment 
Most of the therapies for HE target ammonia
188
 (Fig. 4). These therapies are based on the knowledge 
gained from better understanding of inter-organ ammonia metabolism and the gut-liver-brain axis. The 
majority of ammonia is produced in the gut and in cirrhosis, the liver is not efficiently able to detoxify 
ammonia into urea. Secondarily, the muscle begins to play an increasingly important role in ammonia 
metabolism. In cirrhosis, apart from the urea cycle, 2 other enzymes are crucially important in 
maintaining ammonia homeostasis: glutamine synthase (predominantly expressed in the liver, muscle 
and kidneys) and glutaminase (predominantly expressed in the gut, liver and kidneys). Therefore, 
reducing ammonia production and preventing ammonia absorption from the gut, in addition to 
manipulating GS and glutaminase are all potential targets that could reduce circulating ammonia levels. 
 
Fig. 4. Therapeutic targets for hepatic encephalopathy. 
Ammonia-lowering strategies primarily involve reducing the production or increasing the removal of ammonia. Since a 
large amount of ammonia is produced within the gut, many therapeutics target the gut to reduce the production and 
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absorption of ammonia including rifaximin (non-absorbable antibiotic), lactulose (osmotic laxative), probiotics, activated 
carbon microspheres, engineered bacteria and faecal matter transplantation. Alternatively, stimulating ammonia clearance 
can be targeted via residual hepatocytes (ureagenesis and glutamine synthesis) and/or muscle (glutamine synthesis) with L-
Ornithine L-Aspartate and Ornithine Phenylacetate. Branched chain amino acids (BCAA) benefit the muscle in clearing 
ammonia. The binding properties of albumin remove toxic molecules in circulation via infusion or with extracorporeal 
albumin dialysis. Liposome-supported peritoneal dialysis or glutamine synthetase (GS) replacement can also benefit in 
eliminating ammonia. GABAA-receptor modulating steroid antagonists are centrally acting. = ammonia-derived from 
the gut, = ammonia derived from glutamine, = glutamine generated from muscle. BCAA, branched chain amino 
acids; Gln, glutamine. 
Osmotic laxatives: Non-absorbable disaccharides, lactulose and lactitol, are recommended as first-
line treatment for HE. Lactulose is a laxative which has negligible impact on gut microbiota 
composition or function and likely works through increasing intestinal transit as well as acidification of 
the bowel milieu.
189
 Subsequently, ammonia production is reduced in the gut, faecal excretion is 
increased and ammonia absorption is reduced. Lactulose is the agent most extensively studied in 
patients with an episode of HE. A large number of randomized clinical trials as well as observational 
studies have shown the benefit of lactulose over no therapy, although there are no true double-blinded 
studies as it is extremely difficult to blind for the laxative effect and the typical sweet taste of lactulose. 
A recent Cochrane review demonstrated the beneficial effect of non-absorbable disaccharides on HE 
severity (number needed to treat 4), prevention of HE (number needed to treat 6), mortality (relative 
risk 0.36; 95% CI 0.14–0.94; 172 participants; 6 randomized clinical trials) and on serious adverse 
events such as liver failure, variceal bleeding, serious infections, spontaneous bacterial peritonitis and 
hepatorenal syndrome in randomised clinical trials evaluating episodic HE.
178
 Lactulose therapy is not 
without risks, and potential side effects include diarrhoea, nausea and bloating. Diarrhoea and vomiting 
may lead to electrolyte disturbances, and even exacerbate HE. The dosing of lactulose can be started at 
15–20 ml every 12 hours until 2 soft stools are passed, followed by titration to 2–3 semi-soft 
stools/day. In a randomized controlled trial in hospitalized patients with episodic overt HE compared 
with lactulose therapy, a single dose of polyethylene glycol (PEG) significantly improved the overall 
grade of HE after 24 hours, reduced days to HE resolution, and led to shorter length of hospital stay.
190
 
Before widespread usage, these data need to be confirmed in larger multicentre studies. 
Antimicrobial agents: Rifaximin is a semi-synthetic, non-aminoglycoside which acts against gram+, 
gram-, aerobic and anaerobic enteric bacteria. It binds to the beta subunit of bacterial DNA-dependent 
RNA polymerase, inhibiting bacterial RNA synthesis. It is administered orally and is minimally 
absorbed (>4%), lowering the risk of bacterial resistance. Rifaximin also has negligible impact on 
microbial composition but supposedly has beneficial effects on functionality, reducing secondary bile 
acid production; its effects on bacterial translocation are controversial.
191, 192, 193
 No dose adjustments 
are necessary in patients with liver dysfunction or renal insufficiency. The most solid evidence for the 
utility of rifaximin is use of the drug as an add-on to lactulose to prevent recurrence of HE.
31
 Quality 
evidence is lacking for the use of rifaximin as a monotherapy for the treatment of episodic HE. Large-
scale head-to-head comparisons of lactulose and rifaximin are not available, but in randomised 
controlled trials, rifaximin was as effective as non-absorbable disaccharides or other oral antibiotics in 
the treatment of episodic HE, but with a better safety profile.
194, 195, 196, 197, 198, 199
 Treatment with 
rifaximin has been shown to increase the proportion of patients who recover from HE, as well as 
reducing mortality.
163
 A combination of lactulose plus rifaximin was more effective than lactulose 
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alone for improvement of HE and reduction in mortality, which was due to a decrease in sepsis-related 
deaths. Patients who received lactulose plus rifaximin also had shorter hospital stays.
200
 However, 
further trials of rifaximin plus lactulose are needed before this approach can be considered standard of 
care. 
Probiotics: Probiotics are live bacteria which are believed to improve gut dysbiosis and negatively 
impact ammonia production. A Cochrane systematic review concluded that probiotic treatment may 
lead to improvements in the development of overt HE, quality of life, and lower plasma ammonia but 




Branched-chain amino acids (BCAA): A recent Cochrane systematic review indicated that BCAA 
therapy improved the manifestation of overt HE, while it had no effect on mortality (high quality of 
evidence).
202
 BCAA have been documented to promote muscle protein synthesis and improve muscle 
mass loss, however adequately powered multicentre clinical trials with appropriate control groups 
(comparing with standard interventions) are still required.
202
 
L-ornithine L-aspartate (LOLA): A preliminary meta-analysis of 8 randomised controlled trials 
comparing LOLA with placebo/no-intervention control, suggested that intravenous LOLA improved 
overt HE.
203
 The efficacy of oral LOLA has been a subject of debate, as the AASLD-EASL clinical 





 suggest that LOLA has beneficial effects on HE, decompensation, and mortality, but the number 
of clinical trials analysed was dissimilar in the reports, with one stating that the quality of evidence was 
very low.
206
 Thus, the potential beneficial effect of LOLA remain uncertain. 
Embolisation of portosystemic shunts: In some patients with cirrhosis and HE who are difficult to 
treat or have recurrent episodes, particularly when the liver function is not severely compromised, the 
possibility of a spontaneous large portosystemic shunt should be considered. Although clinical trial 
data in this patient group are limited, many case reports and a large case series from Europe have 
suggested that embolising these shunts can alleviate HE, particularly in patients with a model for end-
stage liver disease score of <11.
207
 More recently, a single centre study suggested that although there 
was significant improvement in the severity of HE in the immediate post-embolisation period, most 
patients developed complications of portal hypertension or died during the following 12 months.
208
 The 
currently available data suggest that shunt embolisation is a useful treatment modality for patients with 
cirrhosis and HE, but that it should be considered a bridge to transplantation in most cases. 
Albumin and extracorporeal albumin dialysis (ECAD): Albumin is a multifunctional protein 
synthesized in the liver, the quantity and quality of which is significantly reduced in patients with 
cirrhosis. Until recently, albumin was thought of as a plasma volume expander. It is now clear that 
albumin has many additional functions including anti-inflammatory properties and the ability to bind 
and clear many toxic substances that accumulate during liver failure. An early uncontrolled non-
randomised study suggested its potential role in the treatment of HE,
209
 but this was not confirmed in a 
randomised controlled clinical trial. The combination of lactulose with albumin was, however, more 
effective than lactulose alone for the complete reversal of HE.
210
 These binding properties of albumin 
© 2020. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-
nd/4.0/  
Rose, C. F.; Amodio, P.; Bajaj, J. S.; Dhiman, R. K.; Montagnese, S.; Taylor-Robinson, S. D.; Vilstrup, H. & Jalan, R. Hepatic 
encephalopathy: Novel insights into classification, pathophysiology and therapy. Journal of Hepatology, 2020 published in final form at 
doi.org/10.1016/j.jhep.2020.07.013. 
Rose, C. F.; Amodio, P.; Bajaj, J. S.; Dhiman, R. K.; Montagnese, S.; Taylor-Robinson, S. D.; Vilstrup, H. & Jalan, R. 
Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy. Journal of Hepatology, 2020 
have been exploited in the ECAD. In 2 randomised, controlled clinical trials of ECAD in patients with 




Alternative strategies: Volume expansion (administering 1 L of 0.9% saline to patients intravenously 
over 1 hour) has been shown to reduce plasma ammonia concentrations by increasing ammonia 
excretion and reducing ammoniagenesis in patients with cirrhosis.
212
 In addition, the use of 
haemofiltration to reduce hyperammonaemia is very effective.
213
 However, high-quality randomised 
clinical trials with standardised outcome collection and data reporting are needed to further clarify the 
true efficacy of these simple alternative strategies. 
Management algorithm for overt hepatic encephalopathy (Fig. 5) 
An episode of overt HE must be actively treated. Precipitating factors must be diligently looked for and 
controlled. Lactulose is the first-line therapy. Quality data is lacking for rifaximin in this setting, either 
as add-on or monotherapy. In patients with episodic HE and ACLF who are difficult to control, ECAD 
should be considered where available. Other agents such as PEG, LOLA, BCAA and albumin should 
be considered safe and potentially useful but cannot be recommended for routine use 
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Fig. 5. Algorithm for the management of a hospitalised patient with overt hepatic 
encephalopathy. 
Once overt hepatic encephalopathy is confirmed, attend to “ABC” management. If hepatic encephalopathy is severe, admit 
to ICU. Management involves identifying correcting the precipitating factor. If patient has hyperammonaemia, ammonia-
lowering strategies are initiated. ICU, intensive care unit. 
PREVENTION OF OVERT HEPATIC ENCEPHALOPATHY 
Primary prophylaxis 
Two recent clinical trials evaluated the efficacy of lactulose or VSL#3, a probiotic preparation, for 
primary prophylaxis of overt HE compared with no treatment in patients with cirrhosis.
214,215
 Child-
Pugh class B/C and presence of mHE at baseline were predictors of development of overt HE. Both 
trials, though from the same centre, have demonstrated that lactulose and VSL#3 are effective in 
preventing the first episode of overt HE. There is also evidence that lactulose treatment reverses mHE, 
prevents overt HE and improves health-related quality of life in patients with liver cirrhosis.
216
 
Therefore, although it seems logical to give primary prophylaxis with lactulose to patients with 
cirrhosis at high risk of overt HE, further multicentre clinical trials are needed to confirm these early 
clinical trial data, considering that lactulose treatment may be difficult to tolerate and is not completely 
without side effects. 
Secondary prophylaxis 
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Patients with cirrhosis who have recovered from an episode of HE are at higher risk of developing 
recurrent episodes of overt HE. Lactulose is effective at preventing the subsequent episode of overt HE 
in patients with cirrhosis but there is no effect on hospitalisation rate or mortality.
30,217
 Rifaximin as 
add-on to lactulose is more effective than lactulose alone in preventing a third breakthrough episode of 
HE and in reducing the risk of hospitalisations involving overt HE.
31
 Long-term treatment with 
rifaximin, as add-on to lactulose, does not increase the rates of adverse events and appears to provide a 
continued reduction in the rate of HE-related and all-cause hospitalisation.
218
 VSL#3, a probiotic 
preparation has also been shown to effectively prevent subsequent episodes of overt HE and reduce 
hospitalisations, but further appropriately powered multicentre studies are required before it can be 
recommended for routine use.
219
 More recently, in a randomised controlled clinical trial, long-term 
albumin administration to patients with decompensated cirrhosis was associated with a reduction in the 
occurrence of most of the major complications of cirrhosis (including HE) as well as in mortality.
220
 
EMERGING THERAPIES FOR HEPATIC ENCEPHALOPATHY 
There are exciting, innovative, emerging therapies for HE that are currently being developed at the pre-
clinical phase, as well as options currently being tested in clinical trials (Fig. 4). 
CLINICAL STAGE 
Ornithine phenylacetate (OP): The combination of ornithine and phenylacetate was designed to 
increase muscle ammonia detoxification via the stimulation of the enzyme GS. This results in the 
production of glutamine, which is converted to phenylacetylglutamine – to avoid glutamine metabolism 
– via glutaminase and ammonia regeneration.
221
 In addition, it has been demonstrated that OP also 
chelates glycine, another ammoniagenic amino acid.
222
 OP significantly lowers blood ammonia in a 
number of different animal models of liver disease/failure.
59,223,224
 In a preliminary communication, the 
results of a phase 2b study were described, which showed that OP reduced ammonia concentrations in 
patients with overt HE in a dose-dependent manner but did not meet its primary end-point of time to 
improvement in HE.
225
 A phase III study is being planned. 
Glycerol/sodium phenylbutyrate: Sodium phenylbutyrate is a treatment of choice for patients with 
genetic urea cycle disorders. In a small study, it was recently demonstrated to improve neurological 
outcome in association with lowering blood ammonia in patients with cirrhosis treated in an intensive 
care unit setting.
226
 Even though this study did not include a control arm, the associations between 
neurological improvement and change in blood ammonia are important. In a randomized, double-blind, 
controlled study, glycerol phenylbutyrate was demonstrated to lower ammonia and significantly reduce 
the proportion of patients who experienced a HE event, as well as reducing HE hospitalisations.
41
 
Whether glycerol phenylbutyrate will continue to develop as a treatment for HE is not clear. 
Faecal microbiota transplantation:  Faecal microbiota transplantation (FMT) from healthy donors 
has been given to patients with cirrhosis to ameliorate the gut's microbial dysbiosis. Recent secondary 
results from a safety protocol suggest a beneficial effect on cognition in patients with HE receiving an 
FMT.
227, 228, 229
 These encouraging results have been associated with enrichment of supposedly 
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beneficial taxa. However, the understanding of how and why certain taxa are beneficial remains 
unknown. 
PRE-CLINICAL STAGE 
Liposome-supported peritoneal dialysis (LSPD): Dialysis fluids supplemented with micrometre-
sized, transmembrane pH-gradient liposomes were developed as a detoxification strategy for the 
removal of small ionizable molecules such as ammonia. LSPD was able to sequester ammonia in a rat 




Engineered bacteria: Genetically modified E. coli nissle have been programmed to metabolise 
ammonia. Orally administered, they have been shown to lower blood ammonia in an animal model of 
liver injury (thioacetamide-induced) as well as in animals with ornithine transcarbamylase-deficiency 
(model of urea cycle disorder).
231
 However, the clinical study in patients with cirrhosis did not meet the 
endpoint for ammonia reduction.
232
 
Activated carbon microspheres: Designed to adsorb ammonia and other organic compounds in the 
gut, AST-120 demonstrated promising results by lowering blood ammonia in an animal model of liver 
disease.
233
 However, AST-120 did not meet the primary endpoint in a phase II clinical study (ASTUTE 
trial). This may to some extent be related to the trial design and activated carbon microspheres merit 
further development. 
GABAA receptor-modulating steroid antagonists (GAMSA): Patients with HE have increased 
GABA-ergic tone, potentiated by neurosteroids which contribute to their neuroinhibition. A new drug 
of 3-beta-hydroxysteroid conformation is shown to effectively antagonise this mechanism and restore 
brain function in rats with experimental hyperammonaemia and HE and to counteract the effects of 
administered neurosteroids in healthy individuals.
234,235
 The drug is presently under clinical 
investigation and has recently been identified as a therapeutic target for HE.
236
 
Glutamine synthetase (GS) replacement: Glutamine is an important intermediate in ammonia 
metabolism, particularly when the urea cycle is dysfunctional, as it is in patients with liver disease. The 
main site for the localisation of GS is in the liver and muscle. In ALF and CLD models, GS has been 
shown to be upregulated in the muscle.
237, 238, 239
 Knocking out GS selectively in the liver
240
 and/or the 
muscle
241
 resulted in hyperammonaemia. Reconstitution of GS in an animal model of 
hyperammonaemia was effective in reducing ammonia levels.
242
 These data provided the rationale for 
the development of a strategy for GS enzyme induction or replacement therapy. Preliminary data from 
a study showed that AM-535, which is a recombinant GS, reduced ammonia effectively in an animal 
model of cirrhosis and urea cycle enzyme disorder.
243
 
CONTROVERSIES, FUTURE RESEARCH AND CONCLUSIONS 
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Although there has been a considerable increase in our understanding of the pathophysiology of the 
syndrome, targeting ammonia and inflammation remains the cornerstone of treatment. The main 
controversies relate to classification of HE and the role of ammonia measurements in the management 
of patients. It is clear that the diagnosis of Grade 1 HE is difficult – whether this term should be 
dropped altogether is under intense discussion. Although there are arguments for ammonia 
measurement as an aid to patient management, doing this accurately in clinical practice remains 
challenging. Future research should be directed at understanding the impact of comorbidities on 
outcomes, testing strategies that target systemic- and neuroinflammation and providing guidance to 
drug developers and regulators on clear endpoints. With the improvements in MR technology, research 
needs to further develop MR-based methodology to personalise prophylactic and therapeutic 
approaches for patients with HE. Finally, the increasing understanding of the terrible quality of life 
endured by patients with HE and their relatives highlights the need for new tools to better monitor and 
manage patients in their homes. In conclusion, it is clear that HE remains one of the most important 
complications of cirrhosis, contributing both to the morbidity and mortality of patients with cirrhosis, 
while considerable advances in our understanding are now being translated into improving clinical 
outcomes. 
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